Rivastigmine in outpatient services: Experience of 114 neurologists in Austria

International Clinical Psychopharmacology

Volumn 17, Issue 2, 2002, Pages 81-85

  Schmidt, Reinhold ^a   Lechner, A ^a   Petrovic, K ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Alzheimers disease; Clinical routine; Rivastigmine; Treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ADULT; AGED; AGGRESSION; ALZHEIMER DISEASE; APPETITE DISORDER; ARTICLE; CLINICAL PRACTICE; COGNITION; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MENTAL HEALTH; NAUSEA; NEUROTOXICITY; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RATING SCALE; TITRIMETRY; TREATMENT OUTCOME; TREMOR; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 0036187116     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200203000-00007     Document Type: Article

References (8)

1. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimers disease
2. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimers disease
3. Estimating long term cost savings from treatment of Alzheimers disease
4. Mini mental state: A practical method for grading the cognitive state of patients for the clinician
5. Treatment of Alzheimers disease
6. Clinical Diagnosis of Alzheimers diesease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimers disease
7. The global deterioration scale for the assessment of primary degenerative dementia
8. Efficacy and safety of rivastigmine in patients with Alzheimers disease: International randomised controlled trial